Pub Date : 2022-11-01DOI: 10.1016/S2667-3762(22)00059-2
{"title":"TOC","authors":"","doi":"10.1016/S2667-3762(22)00059-2","DOIUrl":"https://doi.org/10.1016/S2667-3762(22)00059-2","url":null,"abstract":"","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 3","pages":"Article 100082"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376222000592/pdfft?md5=8aa0285fb9e8baf661d53dfdab33793a&pid=1-s2.0-S2667376222000592-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92031895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1016/j.aopr.2022.100064
Xintong Xu , Lindan Xie , Lili Wei , Meixuan Li , Hao Wang , Huanfen Zhou , Mingming Sun , Mo Yang , Quangang Xu , Kehu Yang , Shihui Wei
Background
Monoclonal antibodies such as rituximab (RTX), eculizumab, inebilizumab, satralizumab, and tocilizumab have been found to be effective therapies for neuromyelitis optica spectrum disease (NMOSD) in several clinical randomized controlled trials.
Objective
The purpose of this meta-analysis of randomized controlled trials was to assess the efficacy and safety of monoclonal antibodies in the treatment of NMOSD.
Methods
We searched the following databases for relevant English language literature from the establishment of the database to June 2021: PubMed, Embase, Cohorane Library, the Central Register of Controlled Trials (CENTRAL), and Web of Science. Randomized controlled trials of monoclonal antibodies were the targets of the review.
Results
We included seven trials containing 775 patients (485 in the monoclonal antibody group and 290 in the control group). Patients in the monoclonal group (HR 0.24, 95% CI: 0.14 to 0.40, P < 0.00001), as well as patients with seropositive AQP4-IgG (HR 0.18, 95% CI: 0.11 to 0.29, P < 0.00001), both had a higher free recurrence rate than that in the control group. In the first year (HR 0.25, 95% CI: 0.09 to 0.71, P = 0.009) and the second year (HR 0.32, 95% CI: 0.13 to 0.81, P = 0.02), no relapses were documented. The average changes of the expanded disability status scale (EDSS) score decreased by 0.29 (95% CI: −0.09 to 0.51, P = 0.005). Upper respiratory tract infection (OR 1.52, 95% CI: 0.76 to 3.04, P = 0.24), urinary tract infection(OR 0.79, 95% CI: 0.51 to 1.21, P = 0.27), and headache (OR 1.30, 95% CI: 0.78 to 2.17, P = 0.31) were three most frequent adverse reactions.
Conclusions
Monoclonal antibodies are particularly effective treatments in avoiding recurrence for NMOSD patients, according to this meta-analysis. The associated adverse responses are not significantly different from those seen with traditional immunosuppressants.
在一些临床随机对照试验中，单克隆抗体如利妥昔单抗(RTX)、eculizumab、inebilizumab、satralizumab和tocilizumab已被发现是治疗视神经脊髓炎(NMOSD)的有效方法。目的本荟萃分析的目的是评估单克隆抗体治疗NMOSD的疗效和安全性。方法检索自建库至2021年6月的相关英文文献:PubMed、Embase、Cohorane Library、Central Register of Controlled Trials (Central)和Web of Science。该综述的目标是单克隆抗体的随机对照试验。结果纳入7项试验，共775例患者(单克隆抗体组485例，对照组290例)。单克隆组患者(HR 0.24, 95% CI: 0.14 ~ 0.40, P <0.00001)，以及血清AQP4-IgG阳性患者(HR 0.18, 95% CI: 0.11 ~ 0.29, P <0.00001)，两组游离复发率均高于对照组。第一年(HR 0.25, 95% CI: 0.09 ~ 0.71, P = 0.009)和第二年(HR 0.32, 95% CI: 0.13 ~ 0.81, P = 0.02)均无复发记录。扩展残疾状态量表(EDSS)评分的平均变化减少了0.29 (95% CI:−0.09 ~ 0.51,P = 0.005)。上呼吸道感染(OR 1.52, 95% CI: 0.76 ~ 3.04, P = 0.24)、尿路感染(OR 0.79, 95% CI: 0.51 ~ 1.21, P = 0.27)和头痛(OR 1.30, 95% CI: 0.78 ~ 2.17, P = 0.31)是三个最常见的不良反应。结论根据这项荟萃分析，单克隆抗体是避免NMOSD患者复发的有效治疗方法。相关的不良反应与传统免疫抑制剂的不良反应没有显著差异。
{"title":"Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials","authors":"Xintong Xu , Lindan Xie , Lili Wei , Meixuan Li , Hao Wang , Huanfen Zhou , Mingming Sun , Mo Yang , Quangang Xu , Kehu Yang , Shihui Wei","doi":"10.1016/j.aopr.2022.100064","DOIUrl":"10.1016/j.aopr.2022.100064","url":null,"abstract":"<div><h3>Background</h3><p>Monoclonal antibodies such as rituximab (RTX), eculizumab, inebilizumab, satralizumab, and tocilizumab have been found to be effective therapies for neuromyelitis optica spectrum disease (NMOSD) in several clinical randomized controlled trials.</p></div><div><h3>Objective</h3><p>The purpose of this meta-analysis of randomized controlled trials was to assess the efficacy and safety of monoclonal antibodies in the treatment of NMOSD.</p></div><div><h3>Methods</h3><p>We searched the following databases for relevant English language literature from the establishment of the database to June 2021: PubMed, Embase, Cohorane Library, the Central Register of Controlled Trials (CENTRAL), and Web of Science. Randomized controlled trials of monoclonal antibodies were the targets of the review.</p></div><div><h3>Results</h3><p>We included seven trials containing 775 patients (485 in the monoclonal antibody group and 290 in the control group). Patients in the monoclonal group (HR 0.24, 95% CI: 0.14 to 0.40, <em>P</em> < 0.00001), as well as patients with seropositive AQP4-IgG (HR 0.18, 95% CI: 0.11 to 0.29, <em>P</em> < 0.00001), both had a higher free recurrence rate than that in the control group. In the first year (HR 0.25, 95% CI: 0.09 to 0.71, <em>P</em> = 0.009) and the second year (HR 0.32, 95% CI: 0.13 to 0.81, <em>P</em> = 0.02), no relapses were documented. The average changes of the expanded disability status scale (EDSS) score decreased by 0.29 (95% CI: −0.09 to 0.51, <em>P</em> = 0.005). Upper respiratory tract infection (OR 1.52, 95% CI: 0.76 to 3.04, <em>P</em> = 0.24), urinary tract infection(OR 0.79, 95% CI: 0.51 to 1.21, <em>P</em> = 0.27), and headache (OR 1.30, 95% CI: 0.78 to 2.17, <em>P</em> = 0.31) were three most frequent adverse reactions.</p></div><div><h3>Conclusions</h3><p>Monoclonal antibodies are particularly effective treatments in avoiding recurrence for NMOSD patients, according to this meta-analysis. The associated adverse responses are not significantly different from those seen with traditional immunosuppressants.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 3","pages":"Article 100064"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/d2/main.PMC10577852.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-01DOI: 10.1016/j.aopr.2022.100078
Kai Jin, Juan Ye
Background
The ophthalmology field was among the first to adopt artificial intelligence (AI) in medicine. The availability of digitized ocular images and substantial data have made deep learning (DL) a popular topic.
Main text
At the moment, AI in ophthalmology is mostly used to improve disease diagnosis and assist decision-making aiming at ophthalmic diseases like diabetic retinopathy (DR), glaucoma, age-related macular degeneration (AMD), cataract and other anterior segment diseases. However, most of the AI systems developed to date are still in the experimental stages, with only a few having achieved clinical applications. There are a number of reasons for this phenomenon, including security, privacy, poor pervasiveness, trust and explainability concerns.
Conclusions
This review summarizes AI applications in ophthalmology, highlighting significant clinical considerations for adopting AI techniques and discussing the potential challenges and future directions.
{"title":"Artificial intelligence and deep learning in ophthalmology: Current status and future perspectives","authors":"Kai Jin, Juan Ye","doi":"10.1016/j.aopr.2022.100078","DOIUrl":"10.1016/j.aopr.2022.100078","url":null,"abstract":"<div><h3>Background</h3><p>The ophthalmology field was among the first to adopt artificial intelligence (AI) in medicine. The availability of digitized ocular images and substantial data have made deep learning (DL) a popular topic.</p></div><div><h3>Main text</h3><p>At the moment, AI in ophthalmology is mostly used to improve disease diagnosis and assist decision-making aiming at ophthalmic diseases like diabetic retinopathy (DR), glaucoma, age-related macular degeneration (AMD), cataract and other anterior segment diseases. However, most of the AI systems developed to date are still in the experimental stages, with only a few having achieved clinical applications. There are a number of reasons for this phenomenon, including security, privacy, poor pervasiveness, trust and explainability concerns.</p></div><div><h3>Conclusions</h3><p>This review summarizes AI applications in ophthalmology, highlighting significant clinical considerations for adopting AI techniques and discussing the potential challenges and future directions.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 3","pages":"Article 100078"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/e8/main.PMC10577833.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To determine the possible use of near-infrared(NIR) light-emitting-diode (LED) radiation for imaging intraocular tumours by transpalpebral transillumination.
Methods
This study was a pilot, open-label, prospective and non-interventional. Thirty patients (30 eyes; age 30–72 years) with uveal melanomas located in the iris, ciliary body, or choroid were under our observation. A biomicroscopy, ophthalmoscopy, transpalpebral NIR transillumination, and ultrasound examination were performed in all cases.
Results
In all cases, NIR transillumination with transpalpebral approach enables visualization of the ciliary body and accurately estimates the projection of the pars plicata and ora serrata onto the sclera. In all patients, transpalpebral NIR transillumination made it possible to image the shadow of intraocular melanoma, estimate its dimensions and location concerning the ciliary body structures.
Conclusions
We recommend the non-invasive transpalpebral NIR transillumination technique, together with traditional ultrasound imaging, to improve the accuracy of assessing the size and location of intraocular tumours.
{"title":"Intraocular tumours imaging with transpalpebral near-infrared LED transillumination: Pilot study","authors":"Oleg Zadorozhnyy, Andrii Korol, Taras Kustryn, Nataliya Pasyechnikova","doi":"10.1016/j.aopr.2022.100052","DOIUrl":"10.1016/j.aopr.2022.100052","url":null,"abstract":"<div><h3>Purpose</h3><p>To determine the possible use of near-infrared(NIR) light-emitting-diode (LED) radiation for imaging intraocular tumours by transpalpebral transillumination.</p></div><div><h3>Methods</h3><p>This study was a pilot, open-label, prospective and non-interventional. Thirty patients (30 eyes; age 30–72 years) with uveal melanomas located in the iris, ciliary body, or choroid were under our observation. A biomicroscopy, ophthalmoscopy, transpalpebral NIR transillumination, and ultrasound examination were performed in all cases.</p></div><div><h3>Results</h3><p>In all cases, NIR transillumination with transpalpebral approach enables visualization of the ciliary body and accurately estimates the projection of the pars plicata and ora serrata onto the sclera. In all patients, transpalpebral NIR transillumination made it possible to image the shadow of intraocular melanoma, estimate its dimensions and location concerning the ciliary body structures.</p></div><div><h3>Conclusions</h3><p>We recommend the non-invasive transpalpebral NIR transillumination technique, together with traditional ultrasound imaging, to improve the accuracy of assessing the size and location of intraocular tumours.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/8d/main.PMC10577822.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-01DOI: 10.1016/j.aopr.2022.100060
Jinfeng Liu , Andre K.H. Ma , Kwok Fai So , Vincent W.H. Lee , Kin Chiu
Background
In the last two decades, electrical stimulation (ES) has been tested in patients with various eye diseases and shows great treatment potential in retinitis pigmentosa and optic neuropathy. However, the clinical application of ES in ophthalmology is currently limited. On the one hand, optimization and standardization of ES protocols is still an unmet need. On the other hand, poor understanding of the underlying mechanisms has hindered clinical exploitation.
Main Text
Numerous experimental studies have been conducted to identify the treatment potential of ES in eye diseases and to explore the related cellular and molecular mechanisms. In this review, we summarized the in vitro and in vivo evidence related to cellular and tissue response to ES in eye diseases. We highlighted several pathways that may be utilized by ES to impose its effects on the diseased retina.
Conclusions
Therapeutic effect of ES in retinal degenerative diseases might through preventing neuronal apoptosis, promoting neuronal regeneration, increasing neurotrophic factors production in Müller cells, inhibiting microglial activation, enhancing retinal blood flow, and modulating brain plasticity. Future studies are suggested to analyse changes in specific retinal cells for optimizing the treatment parameters and choosing the best fit ES delivery method in target diseases.
{"title":"Mechanisms of electrical stimulation in eye diseases: A narrative review","authors":"Jinfeng Liu , Andre K.H. Ma , Kwok Fai So , Vincent W.H. Lee , Kin Chiu","doi":"10.1016/j.aopr.2022.100060","DOIUrl":"10.1016/j.aopr.2022.100060","url":null,"abstract":"<div><h3>Background</h3><p>In the last two decades, electrical stimulation (ES) has been tested in patients with various eye diseases and shows great treatment potential in retinitis pigmentosa and optic neuropathy. However, the clinical application of ES in ophthalmology is currently limited. On the one hand, optimization and standardization of ES protocols is still an unmet need. On the other hand, poor understanding of the underlying mechanisms has hindered clinical exploitation.</p></div><div><h3>Main Text</h3><p>Numerous experimental studies have been conducted to identify the treatment potential of ES in eye diseases and to explore the related cellular and molecular mechanisms. In this review, we summarized the in vitro and in vivo evidence related to cellular and tissue response to ES in eye diseases. We highlighted several pathways that may be utilized by ES to impose its effects on the diseased retina.</p></div><div><h3>Conclusions</h3><p>Therapeutic effect of ES in retinal degenerative diseases might through preventing neuronal apoptosis, promoting neuronal regeneration, increasing neurotrophic factors production in Müller cells, inhibiting microglial activation, enhancing retinal blood flow, and modulating brain plasticity. Future studies are suggested to analyse changes in specific retinal cells for optimizing the treatment parameters and choosing the best fit ES delivery method in target diseases.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100060"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/5c/main.PMC10577855.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-01DOI: 10.1016/S2667-3762(22)00047-6
{"title":"TOC","authors":"","doi":"10.1016/S2667-3762(22)00047-6","DOIUrl":"https://doi.org/10.1016/S2667-3762(22)00047-6","url":null,"abstract":"","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100070"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376222000476/pdfft?md5=495c7fe0af3dceaca80e7963779ac0e1&pid=1-s2.0-S2667376222000476-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137217137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-01DOI: 10.1016/j.aopr.2022.100051
Zhiqing Chen , Binbin Chen , Peike Hu , Haipeng Liu , Dingchang Zheng
Purpose
To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME).
Methods
It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant.
Results
No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P > 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images.
Conclusions
PBM is a safe and effective treatment of DME, which deserves further investigation.
{"title":"A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema","authors":"Zhiqing Chen , Binbin Chen , Peike Hu , Haipeng Liu , Dingchang Zheng","doi":"10.1016/j.aopr.2022.100051","DOIUrl":"10.1016/j.aopr.2022.100051","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME).</p></div><div><h3>Methods</h3><p>It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. <em>P</em> < 0.05 was considered statistically significant.</p></div><div><h3>Results</h3><p>No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ± 12.47 and 79.50 ± 10.85, maximal retinal thickness in macular area was 390.95 ± 77.12 μm and 354.13 ± 55.03 μm, average retinal thickness in macular area was 334.25 ± 36.45 μm and 314.31 ± 33.28 μm, foveal thickness was 287.00 ± 46.79 μm and 265.63 ± 67.14 μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (<em>P</em> < 0.05). All follow-up results of foveal thickness were not significantly different (<em>P</em> > 0.05) from the baseline result, except that in the 6th month (<em>P</em> = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images.</p></div><div><h3>Conclusions</h3><p>PBM is a safe and effective treatment of DME, which deserves further investigation.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100051"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/38/main.PMC10577862.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To evaluate the impact of video and verbal counselling on patients' undergoing phacoemulsification under topical anaesthesia.
Methods
This is a prospective randomized controlled trial conducted at Aravind Eye Care System, Pondicherry, India. All patients had a 15 min one-on-one verbal counselling covering surgical technique, implant options, anaesthesia and payment options one day prior to surgery. On the day of surgery, patients were randomized into two groups; in the first group, patients were provided with video counselling and in the second group, patients were given verbal counselling prior to undergoing phacoemulsification under topical anaesthesia. Measurements of blood pressure, heart rate, respiration rate, and the Likert-scale anxiety rating were collected at preoperative, perioperative, and postoperative time points.
Results
A group of 186 patients (aged 45–70 years) were provided video counselling via portable iPad before first-time phacoemulsification, and a second group of 186 patients underwent surgery with verbal counselling. Systolic and diastolic blood pressure measurements were lower in both the video and verbally counselled groups during the intraoperative time point. Furthermore, during the intraoperative period, 123 (66.1%) video counselled patients felt relaxed compared to 119 (64%) patients who were provided verbal counselling (P = 0.6636). Patient cooperation during surgery was excellent in 76(40.9%) video counselled patients and 67(36%) verbally counselled patients (P = 0.3374). 25.8% and 21% (P = 0.2703) of patients experienced no pain during surgery in the video and verbal counselled groups respectively.
Conclusions
Although measures such as pulse rate, respiratory rate and feelings of relaxation did not show significant differences among the two groups of video and verbal counselling, patients marked cooperation during surgery and furthermore, the level of anxiety is most reassuring.
{"title":"Effect of Video Counselling Versus Verbal Counselling on Patient's experience during phacoemulsification under topical anaesthesia","authors":"Merlin Benzy , Rengaraj Venkatesh , Vivekanandan Vellam Ramakrishnan , Varshini Santhanarajan Odayar","doi":"10.1016/j.aopr.2022.100050","DOIUrl":"10.1016/j.aopr.2022.100050","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the impact of video and verbal counselling on patients' undergoing phacoemulsification under topical anaesthesia.</p></div><div><h3>Methods</h3><p>This is a prospective randomized controlled trial conducted at Aravind Eye Care System, Pondicherry, India. All patients had a 15 min one-on-one verbal counselling covering surgical technique, implant options, anaesthesia and payment options one day prior to surgery. On the day of surgery, patients were randomized into two groups; in the first group, patients were provided with video counselling and in the second group, patients were given verbal counselling prior to undergoing phacoemulsification under topical anaesthesia. Measurements of blood pressure, heart rate, respiration rate, and the Likert-scale anxiety rating were collected at preoperative, perioperative, and postoperative time points.</p></div><div><h3>Results</h3><p>A group of 186 patients (aged 45–70 years) were provided video counselling via portable iPad before first-time phacoemulsification, and a second group of 186 patients underwent surgery with verbal counselling. Systolic and diastolic blood pressure measurements were lower in both the video and verbally counselled groups during the intraoperative time point. Furthermore, during the intraoperative period, 123 (66.1%) video counselled patients felt relaxed compared to 119 (64%) patients who were provided verbal counselling (<em>P</em> = 0.6636). Patient cooperation during surgery was excellent in 76(40.9%) video counselled patients and 67(36%) verbally counselled patients (<em>P</em> = 0.3374). 25.8% and 21% (<em>P</em> = 0.2703) of patients experienced no pain during surgery in the video and verbal counselled groups respectively.</p></div><div><h3>Conclusions</h3><p>Although measures such as pulse rate, respiratory rate and feelings of relaxation did not show significant differences among the two groups of video and verbal counselling, patients marked cooperation during surgery and furthermore, the level of anxiety is most reassuring.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100050"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/19/main.PMC10577861.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-01DOI: 10.1016/j.aopr.2022.100049
Ajeet M. Wagle , Smita R. Hegde , Srinivasan Sanjay , Kah-Guan Au Eong
Purpose
Dengue fever (DF) epidemics in Singapore in 2005–2006 and 2007 were caused predominantly by dengue virus serotypes 1 (DENV-1) and 2 (DENV-2) respectively. We investigated the prevalence of ophthalmic manifestations during these consecutive epidemics.
Methods
Seropositive DF patients admitted to the hospital during two separate dengue epidemics were enrolled from June 2005 to December 2007. Demographic, ophthalmic, and laboratory data were collected. The primary outcome measures were differences in ophthalmic and laboratory features across the two epidemics. Factors associated with increased risk of developing various DF-related ophthalmic manifestations were the secondary outcome measures.
Results
Of the 115 patients enrolled, 109 (94.7%; 33 in 2005–2006 and 76 in 2007) completed the eye screening protocol. Majority of patients were Chinese (65, 59.6%) and males (81, 74.3%). The mean age was 40.8 years (range, 18–87). Colour vision impairment (12 vs 14 [36.4% vs 18.7%]; P = 0.04), cotton wool spots (10 vs 3 [30.3% vs 3.9%]; P < 0.001), bleeding diathesis (7 vs 3 [21.2% vs 3.9%]; P = 0.004) and abnormal liver function (mean alanine amino-transferase [150.2 U/L vs 68.28 U/L; P = 0.001], mean aspartate amino-transferase [196.86 U/L vs 99.53 U/L; P = 0.002], total protein [68.43 g/L vs 72.27 g/L; P = 0.016], serum albumin [36.86 g/L vs 40.5 g/L; P = 0.001]) were noted more often in DF epidemics predominantly caused by DENV-1 compared to DENV-2.
Conclusions
A higher prevalence of colour vision impairment, cotton wool spots, bleeding diathesis, and abnormal liver function was found in DF epidemics predominantly caused by DENV-1 compared to DENV-2.
目的2005-2006年和2007年新加坡登革热流行主要分别由登革热病毒血清型1 (DENV-1)和2 (DENV-2)引起。我们调查了这些连续流行期间眼部表现的患病率。方法收集2005年6月至2007年12月两次登革热流行期间住院的DF血清阳性患者。收集了人口统计学、眼科和实验室数据。主要结局指标是两种流行的眼科和实验室特征的差异。与各种df相关的眼部表现风险增加相关的因素是次要结果测量。结果入组的115例患者中，109例(94.7%;33名(2005-2006年)和76名(2007年)完成了眼部筛查方案。以华人(65例，59.6%)和男性(81例，74.3%)居多。平均年龄40.8岁(18 ~ 87岁)。色觉障碍(12 vs 14 [36.4% vs 18.7%];P = 0.04)，棉毛斑(10 vs 3 [30.3% vs 3.9%];P & lt;0.001)，出血素质(7 vs 3 [21.2% vs 3.9%];P = 0.004)和肝功能异常(平均丙氨酸氨基转移酶[150.2 U/L vs 68.28 U/L;P = 0.001]，平均天冬氨酸氨基转移酶[196.86 U/L vs 99.53 U/L;P = 0.002),血清总蛋白(68.43 g / L和72.27 g / L;P = 0.016),血清白蛋白(36.86 g / L和40.5 g / L;P = 0.001])在主要由DENV-1引起的登革热流行中比由DENV-2引起的登革热流行更常见。结论以DENV-1为主的DF流行中色觉障碍、棉斑、出血、肝功能异常的发生率高于DENV-2。
{"title":"Ophthalmic manifestations in seropositive dengue fever patients during epidemics caused by predominantly different dengue serotypes","authors":"Ajeet M. Wagle , Smita R. Hegde , Srinivasan Sanjay , Kah-Guan Au Eong","doi":"10.1016/j.aopr.2022.100049","DOIUrl":"10.1016/j.aopr.2022.100049","url":null,"abstract":"<div><h3>Purpose</h3><p>Dengue fever (DF) epidemics in Singapore in 2005–2006 and 2007 were caused predominantly by dengue virus serotypes 1 (DENV-1) and 2 (DENV-2) respectively. We investigated the prevalence of ophthalmic manifestations during these consecutive epidemics.</p></div><div><h3>Methods</h3><p>Seropositive DF patients admitted to the hospital during two separate dengue epidemics were enrolled from June 2005 to December 2007. Demographic, ophthalmic, and laboratory data were collected. The primary outcome measures were differences in ophthalmic and laboratory features across the two epidemics. Factors associated with increased risk of developing various DF-related ophthalmic manifestations were the secondary outcome measures.</p></div><div><h3>Results</h3><p>Of the 115 patients enrolled, 109 (94.7%; 33 in 2005–2006 and 76 in 2007) completed the eye screening protocol. Majority of patients were Chinese (65, 59.6%) and males (81, 74.3%). The mean age was 40.8 years (range, 18–87). Colour vision impairment (12 vs 14 [36.4% vs 18.7%]; <em>P</em> = 0.04), cotton wool spots (10 vs 3 [30.3% vs 3.9%]; <em>P</em> < 0.001), bleeding diathesis (7 vs 3 [21.2% vs 3.9%]; <em>P</em> = 0.004) and abnormal liver function (mean alanine amino-transferase [150.2 U/L vs 68.28 U/L; <em>P</em> = 0.001], mean aspartate amino-transferase [196.86 U/L vs 99.53 U/L; <em>P</em> = 0.002], total protein [68.43 g/L vs 72.27 g/L; <em>P</em> = 0.016], serum albumin [36.86 g/L vs 40.5 g/L; <em>P</em> = 0.001]) were noted more often in DF epidemics predominantly caused by DENV-1 compared to DENV-2.</p></div><div><h3>Conclusions</h3><p>A higher prevalence of colour vision impairment, cotton wool spots, bleeding diathesis, and abnormal liver function was found in DF epidemics predominantly caused by DENV-1 compared to DENV-2.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/c5/main.PMC10577814.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-01DOI: 10.1016/j.aopr.2022.100048
Jos J. Rozema , Adnan Khan , David A. Atchison
Purpose
To develop a paraxial eye model based on a previously collected cohort of adults with well-controlled type 1 diabetes mellitus (DM1) and a limited range of refractive errors.
Methods
The study used the previously published biometric data of 72 participants (Age: 41.5 ± 12.4 years) with DM1. Measurements included objective refraction, anterior and posterior corneal radii of curvatures, and internal distances. Moreover, phakometry was used to determine the lens radii of curvature and lens equivalent indices, from which the lens powers were calculated. A multivariate linear regression was performed for each biometric parameter with respect to current age (Age), the time since the onset of diabetes (Tdb), and current levels of glycated hemoglobin (HbA1c). The vitreous chamber depth was determined from other distances, and lens equivalent index was chosen to balance the models. These were compared with an existing model for non-diabetic eyes.
Results
Some dependent parameters were not affected by the independent variables (spherical equivalent, anterior corneal radius of curvature, central corneal thickness), some were affected by time since onset (the lens radii of curvatures, anterior chamber depth) and others were affected by both age and time since onset (posterior corneal radius of curvature, lens thickness, axial length). None of the dependent parameters were affected by current levels of HbA1c.
Conclusions
The proposed model accurately describes the age-related changes in the eyes of people with DM1. In this description the age of diabetes onset plays an important role, especially if the diabetes onset occurred during childhood.
{"title":"Modelling ocular ageing in adults with well-controlled type I diabetes","authors":"Jos J. Rozema , Adnan Khan , David A. Atchison","doi":"10.1016/j.aopr.2022.100048","DOIUrl":"10.1016/j.aopr.2022.100048","url":null,"abstract":"<div><h3>Purpose</h3><p>To develop a paraxial eye model based on a previously collected cohort of adults with well-controlled type 1 diabetes mellitus (<em>DM1</em>) and a limited range of refractive errors.</p></div><div><h3>Methods</h3><p>The study used the previously published biometric data of <em>72</em> participants (Age: <em>41.5 ± 12.4</em> years) with <em>DM1</em>. Measurements included objective refraction, anterior and posterior corneal radii of curvatures, and internal distances. Moreover, phakometry was used to determine the lens radii of curvature and lens equivalent indices, from which the lens powers were calculated. A multivariate linear regression was performed for each biometric parameter with respect to current age (<em>Age</em>), the time since the onset of diabetes (<em>T</em><sub>db</sub>), and current levels of glycated hemoglobin (<em>HbA1c</em>). The vitreous chamber depth was determined from other distances, and lens equivalent index was chosen to balance the models. These were compared with an existing model for non-diabetic eyes.</p></div><div><h3>Results</h3><p>Some dependent parameters were not affected by the independent variables (spherical equivalent, anterior corneal radius of curvature, central corneal thickness), some were affected by time since onset (the lens radii of curvatures, anterior chamber depth) and others were affected by both age and time since onset (posterior corneal radius of curvature, lens thickness, axial length). None of the dependent parameters were affected by current levels of <em>HbA1c</em>.</p></div><div><h3>Conclusions</h3><p>The proposed model accurately describes the age-related changes in the eyes of people with <em>DM1</em>. In this description the age of diabetes onset plays an important role, especially if the diabetes onset occurred during childhood.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"2 2","pages":"Article 100048"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/14/main.PMC10577873.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号